Compare · BNGO vs TXG
BNGO vs TXG
Side-by-side comparison of Bionano Genomics Inc. (BNGO) and 10x Genomics Inc. (TXG): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BNGO and TXG operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- TXG is the larger of the two at $9.43B, about 584.6x BNGO ($16.1M).
- TXG has been more active in the news (9 items in the past 4 weeks vs 1 for BNGO).
- TXG has more recent analyst coverage (25 ratings vs 5 for BNGO).
- Company
- Bionano Genomics Inc.
- 10x Genomics Inc.
- Price
- -
- -
- Market cap
- $16.1M
- $9.43B
- 1M return
- -
- -9.24%
- 1Y return
- -
- +490.87%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2019
- News (4w)
- 1
- 9
- Recent ratings
- 5
- 25
Bionano Genomics Inc.
Bionano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes. Its Saphyr system includes an instrument, chip consumables, reagents, a suite of data analysis tools, and genome analysis services for researchers to evaluate optical genome mapping data. The company's Bionano prep kits and labeling kits provide the reagents and protocols needed to extract and label ultra-high molecular weight DNA for use with the Saphyr system; and data solutions offering includes a suite of hardware and software for end-to-end experiment management, algorithms for assembling genome maps, and algorithms and databases for bioinformatics processing. It sells its products for research use applications primarily to laboratories associated with academic and governmental research institutions, as well as to pharmaceutical, biotechnology, and contract research companies in the United States and Canada, Europe, the Middle East, India, Africa, China, Japan, South Korea, Singapore, and Australia. Bionano Genomics, Inc. has a procurement and collaboration agreement with NuProbe, Inc. for research and product development in the fields of reproductive health and oncology liquid biopsies. The company was formerly known as BioNano Genomics, Inc. and changed its name to Bionano Genomics, Inc. in July 2018. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
10x Genomics Inc.
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Latest BNGO
- Bionano Laboratories Announces Expansion of Diagnostic Testing Based on Optical Genome Mapping for Hematologic Malignancies
- Bionano Announces Three New Peer-Reviewed Studies Demonstrate Clinical Value of Bionano's Optical Genome Mapping Across Myelodysplastic Syndromes and Acute Myeloid Leukemia
- Bionano Genomics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Bionano Laboratories Announces Proposed Local Coverage Determination (LCD) from MolDX for Genome-Wide Detection of Structural Variants in Hematologic Neoplasms
- Interim Chief Executive Luderer Albert bought $4,845 worth of shares (4,000 units at $1.21) (SEC Form 4)
- Bionano Laboratories Announces New York State Department of Health Approval of Lab Developed Tests Based on Optical Genome Mapping
- Bionano to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
- Interim Chief Executive Luderer Albert bought $4,860 worth of shares (4,000 units at $1.22) (SEC Form 4)
- SEC Form 10-Q filed by Bionano Genomics Inc.
- Bionano Genomics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest TXG
- 10x Genomics to Report Third Quarter 2026 Financial Results on November 5, 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by 10x Genomics Inc.
- 10x Genomics Announces New Collaboration to Advance Single Cell and Spatial Applications Across Solid Tumors and Blood Cancers
- 10x Genomics Announces Sentira, a New Computational Platform to Turn Complex Biological Data Into Experimental Conclusions
- 10x Genomics Begins Global Shipments of Atera, Putting Unprecedented Spatial Biology Capabilities in Researchers' Hands
- Argus initiated coverage on 10x Genomics with a new price target
- Director Suliman Shehnaaz sold $464,668 worth of shares (5,723 units at $81.19) as part of a pre-agreed trading plan, decreasing direct ownership by 19% to 23,792 units (SEC Form 4)
- Chief Executive Officer Saxonov Serge sold $2,030,562 worth of shares (25,000 units at $81.22) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 1,050,249 units (SEC Form 4)
- SEC Form 144 filed by 10x Genomics Inc.
- Chief Financial Officer Taich Adam sold $2,995,470 worth of shares (46,388 units at $64.57) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 316,344 units (SEC Form 4)